Table 1 V-125 reduces lung carcinogenesis in A/J mice.
From: The rexinoid V-125 reduces tumor growth in preclinical models of breast and lung cancer
mg/kg diet | Control | Bexarotene | V-125 | ||
|---|---|---|---|---|---|
40 | 80 | 40 | 80 | ||
# of slides/group | 30 | 28 | 30 | 30 | 28 |
# of tumors/group | 99 | 104 | 81 | 76 | 58 |
Total # tumors/slide (% control) | 3.3 ± 0.35 (100%) | 3.71 ± 0.30 (112.6%) | 2.7 ± 0.26 (81.8%) | 2.53 ± 0.28 (76.8%) | 2.07 ± 0.30* (62.8%) |
Total tumor volume, mm3 | 15.98 | 14.17 | 11.247 | 11.16 | 5.17 |
Ave tumor size (mm3)/tumor (% control) | 0.16 ± 0.01 (100%) | 0.14 ± 0.01 (84.4%) | 0.14 ± 0.02 (84.4%) | 0.15 ± 0.04 (91.0%) | 0.09 ± 0.01* (55.2%) |
Ave tumor burden (mm3) (% control) | 0.53 ± 0.08 (100%) | 0.51 ± 0.07 (95.0%) | 0.37 ± 0.06 (70.4%) | 0.37 ± 0.10 (69.8%) | 0.18 ± 0.04* (34.7%) |
Total # L/M grade (% total) | 43 (43%) | 50 (48%) | 43 (53%) | 38 (50%) | 38 (66%)* |
Total # HH grade (% total) | 56 (57%) | 54 (52%) | 38 (47%) | 38 (50%) | 20 (34%)* |
